Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device ...

Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...

Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

Formulas marketed for toddlers are a burgeoning business, but pediatricians have long recommended against their use.

Abbott Laboratories is forecasting lower-than-expected first-quarter earnings but full-year profit in line with Wall Street ...